21 November
Pure Biologics submits an eIND application to the FDA for the start of Phase 0 in the PB004 project and decides on the further development of PB003G toward Phase 0.
31 March
Pure Biologics has published its annual report for 2021 in which it summarizes its financial results and scientific achievements.
20 December
On December 18, 2021, Pure Biologics signed a contract for the lease of space for a new headquarters.
Menu Close

We use cookies to give you the best browsing experience, site traffic analysis, and advertisement management.

Pure Biologics - Harnessing the power of antibodies and aptamers